Figure 3.

Prospective testing of response to pegylated PH20 hyaluronidase (PEGPH20) as a function of HA phenotype. Squamous cell carcinoma-type NSCLC patient explants were first characterized for HA expression by HA staining [13] using biotinylated HA binding protein and subsequently grown in nude mice to test the hypothesis that the HA⁺³ phenotype (c) would respond more robustly to single-agent PEGPH20 than either the HA⁺² (b) or HA⁺¹ (a) phenotypes. TGI = tumor growth inhibition. Error bars in Figure 3a–c represent SEM of averages of tumor volumes from 10 mice. Reprinted by permission [13]